Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15247214 | 1.00 | MEN1 (0.43) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL22874689 | 1.00 | MEN1 (0.43) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL14147221 | 0.84 | MEN1 (0.46) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL13403905 | 0.84 | MEN1 (0.46) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL14147672 | 0.84 | MEN1 (0.46) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL17540494 | 0.84 | DPP4 (0.45) | MEN1ALDH1A1KMT2AEPHX2DPP4 | |
| SCHEMBL17546275 | 0.82 | ALDH1A1 (0.63) | MEN1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL15247321 | 0.82 | MEN1 (0.44) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL17540518 | 0.82 | MEN1 (0.44) | MEN1ALDH1A1KMT2AEPHX2SMYD3 | |
| SCHEMBL2603237 | 0.82 | MEN1 (0.47) | MEN1ALDH1A1KMT2AEPHX2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3428160-A1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3027603-B1 | HETEROBICYCLOARYL RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | PFIZER (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046597-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | MEN1 3968/4885ALDH1A1 576/4885KMT2A 1687/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | MEN1 2469/4885ALDH1A1 3363/4885KMT2A 765/4885 |
| US-20180086736-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | MEN1 3968/4885ALDH1A1 576/4885KMT2A 1687/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | MEN1 2730/4885ALDH1A1 4009/4885KMT2A 826/4885 |
| US-20170233371-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | MEN1 3968/4885ALDH1A1 576/4885KMT2A 1687/4885 |
| US-20190144429-A1 | RORC2 INHIBITORS AND METHODS OF USE THEREOF | RORC, RORB, RORA | MEN1 3968/4885ALDH1A1 576/4885KMT2A 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.